Clariness today announces its role in supporting Bayer Pharma’s new study review process, which combines international insights from patients, investigators and independent bodies.
As demonstrated at SCOPE 2022, Bayer Pharma is piloting a new 360° study review process aimed at combining insights from different trial stakeholders to design more patient-centric trials that boost enrolment and retention. Clariness is supporting this innovative process through providing pre-trial patient insights, as well as patient exit experiences and feedback, to ensure true patient centricity.
“We hope to set a new industry standard for study reviews, and in doing so, create better trial experiences for patients and sites. Clariness provides us with unfiltered access to patient voices, which allows us to create better patient experiences at every stage of our study.” said Silke Strommenger, Head Feasibility, CDO of Bayer Pharma.
While traditionally pharma/biotech companies only gather limited insights and feedback from a few parties on a regional level, this international and holistic approach is believed to be the future of study reviews. “It’s really encouraging to see a leading sponsor like Bayer Pharma pilot this process, leveraging insights from multiple parties on a global level. At this time, we believe this to be an industry gold standard, but hope it becomes the norm in years to come,” commented Michael Stadler, CEO of Clariness.
The process piloted has collected investigator and independent expert insights on study design, endpoints and recruitment, from the US, the UK, Spain and Sweden. The patient insights gathered through Clariness provide feedback on the study experience and preferences, as well as current treatments, from the US, Germany, the Czech Republic and Poland.
“As we pilot this holistic study review process, we expect to provide a better experience for patients throughout their trial journey, and in-turn, see higher randomisation and retention rates, leading to shorter clinical trial timelines,” said Sven Oechsner, senior strategist of feasibility at Bayer Pharma.